Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8419387 | 0.89 | ALDH1A1 (0.50) | ALDH1A1HPGDMAPK1TSHRHTT | |
| SCHEMBL1644885 | 0.85 | MAPK1 (0.59) | ALDH1A1HPGDMAPK1TSHRHTT | |
| SCHEMBL11254093 | 0.85 | ALDH1A1 (0.46) | ALDH1A1HPGDMAPK1TSHRHTT | |
| SCHEMBL30168125 | 0.85 | ALDH1A1 (0.59) | ALDH1A1HPGDMAPK1TSHRHTT | |
| SCHEMBL3150784 | 0.85 | ALDH1A1 (0.59) | ALDH1A1HPGDMAPK1TSHRHTT | |
| SCHEMBL8421119 | 0.84 | ALDH1A1 (0.52) | ALDH1A1HPGDMAPK1TSHRHTT | |
| SCHEMBL4190286 | 0.84 | ALDH1A1 (0.52) | ALDH1A1HPGDMAPK1TSHRHTT | |
| SCHEMBL1404979 | 0.84 | ALDH1A1 (0.54) | ALDH1A1HPGDMAPK1TSHRHTT | |
| SCHEMBL11766148 | 0.84 | ALDH1A1 (0.52) | ALDH1A1HPGDMAPK1TSHRHTT | |
| SCHEMBL7236261 | 0.83 | ALDH1A1 (0.55) | ALDH1A1HPGDMAPK1TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106635199-B | Reduce the additive of alcohol-based fuel pollutant emission | 山西医科大学 | 2018-04-24 | — | — | CN | claimed |
| CN-106753619-B | Low ratio methanol gasoline additive | 甘肃桑田清洁能源开发有限公司 | 2018-03-09 | — | — | CN | claimed |
| CN-106753619-A | Low ratio methanol gasoline additive | 甘肃桑田清洁能源开发有限公司 | 2017-05-31 | — | — | CN | claimed |
| CN-106635199-A | Additive for reducing discharge of alcohol-based fuel pollutants | 郭四虎 | 2017-05-10 | — | — | CN | claimed |
| CN-116768746-A | Method for synthesizing chiral 2-amido benzhydrol by iridium catalysis | 中国科学院大连化学物理研究所 | 2023-09-19 | — | — | CN | disclosed |
| CN-106635199-B | Reduce the additive of alcohol-based fuel pollutant emission | 山西医科大学 | 2018-04-24 | — | — | CN | disclosed |
| CN-106753619-B | Low ratio methanol gasoline additive | 甘肃桑田清洁能源开发有限公司 | 2018-03-09 | — | — | CN | disclosed |
| CN-106753619-A | Low ratio methanol gasoline additive | 甘肃桑田清洁能源开发有限公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-106635199-A | Additive for reducing discharge of alcohol-based fuel pollutants | 郭四虎 | 2017-05-10 | — | — | CN | disclosed |
| CN-106635199-A | Additive for reducing discharge of alcohol-based fuel pollutants | 郭四虎 | 2017-05-10 | — | — | CN | disclosed |
| US-7442795-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1597260-B1 | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-12-27 | — | — | EP | disclosed |
| US-7119088-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060194794-A1 | Triazole compounds useful in therapy | PFIZER INC | 2006-08-31 | — | — | US | disclosed |
| CN-1751047-A | Triazole compounds useful in therapy | PFIZER (US) | 2006-03-22 | — | — | CN | disclosed |
| EP-1597260-A1 | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2005-11-23 | — | — | EP | disclosed |
| US-20040186091-A1 | A bi-heterocycle-4H-2,3,5,10b-tetraaza-benzo[e]azulene derivatives; for therapy of dysmenorrhoea, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, motion sickness, Raynaud's disease, rheumatoid arthritis; chemical synthesis | PFIZER INC | 2004-09-23 | — | — | US | disclosed |
| WO-2004074291-A1 | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2004-09-02 | — | — | WO | disclosed |
| US-5332739-A | Pyrimidinedione derivatives and antiarrhythmic agents containing same | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1994-07-26 | — | — | US | disclosed |
| EP-0454498-A2 | Pyrimidinedione derivatives and antiarrhythmic agents containing same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194794-A1 | Triazole compounds useful in therapy | CYP3A43, CYP3A5, CYP3A7 | ALDH1A1 940/4885HPGD 895/4885MAPK1 4646/4885 |
| US-20040186091-A1 | A bi-heterocycle-4H-2,3,5,10b-tetraaza-benzo[e]azulene derivatives; for therapy of dysmenorrhoea, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, motion sickness, Raynaud's disease, rheumatoid arthritis; chemical synthesis | CNR1, NR1H2, OXER1 | ALDH1A1 1425/4885HPGD 621/4885MAPK1 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.